Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy

Hematol Oncol. 2018 Feb;36(1):316-319. doi: 10.1002/hon.2445. Epub 2017 Jun 4.

Abstract

Primary effusion lymphoma is a rare non-Hodgkin lymphoma that presents with pleural effusions and lacking of tumour mass. It is universally associated with human herpesvirus 8 (HHV8) and is more frequent among immunosuppressed patients. There is no standard treatment, chemotherapy and anti-HIV therapy have been used with poor results, but there is still no strong evidence supporting the use of valganciclovir. We present the case of a HIV positive man that presented with pleural effusion compatible with primary effusion lymphoma and positivity for HHV8 DNA in blood. Bortezomib-containing treatment protocol was started, but the disease progressed within the chemotherapy. Therefore, treatment with oral valganciclovir was decided and the patient achieved a sustained radiological complete response. HHV8 DNA turned negative 6 months after starting the treatment with valganciclovir.

Keywords: Kaposi sarcoma; aggressive lymphoma; human herpesvirus 8; primary effusion lymphoma; valganciclovir.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Ganciclovir / administration & dosage
  • Ganciclovir / analogs & derivatives*
  • Ganciclovir / pharmacology
  • Ganciclovir / therapeutic use
  • Humans
  • Lymphoma, Primary Effusion / drug therapy*
  • Lymphoma, Primary Effusion / pathology
  • Male
  • Middle Aged
  • Valganciclovir

Substances

  • Valganciclovir
  • Ganciclovir